At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jul 13, 2026 at 16:01 ET
Erasca reported encouraging preliminary Phase 1 data for ERAS-0015, its pan-RAS molecular glue, showing a 57% unconfirmed overall response rate (uORR) at 8 weeks in 2L+ KRAS G12X pancreatic cancer at the 32 mg QD recommended dose. The company outlined accelerated development plans including a potentially registration-enabling trial in lung cancer in H1 2027 and a Phase 3 pancreatic cancer trial in 2027, which for an early-stage biotech is a significant positive catalyst.
- 57% uORR8wk in 2L+ KRAS G12X pancreatic cancer at RDE of 32 mg QD (N=7).
- Median relative dose intensity of 100% at both 24 mg QD and 32 mg QD.
- No DLTs observed; therapy generally well-tolerated with no discontinuations due to TRAEs.
- First dose escalation combination cohort of ERAS-0015 (16 mg) with panitumumab cleared without DLTs.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access